Skip to content

Efficacy and safety of the fixed combinations latanoprost/ timolol versus dorzolamide / timolol in patients with elevated intraocular pressure.

Comparison of the fixed combinations latanoprost/ timolol versus dorzolamide / timolol in patients with primary open angle glaucoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201109047466N1
Enrollment
60
Registered
2011-09-14
Start date
2011-04-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary open-angle glaucoma. Glaucoma primary residual stage: capsular with pseudoexfoliation of lens . chronic simple . low-tension . pigmentary

Interventions

Intervention 1: First group receive Timolol which is a non-specific blocker of beta-adrenergic receptor with concentration of 0.05%, twice daily for six weeks and also Latanoprost which is prostagland
Treatment - Drugs
First group receive Timolol which is a non-specific blocker of beta-adrenergic receptor with concentration of 0.05%, twice daily for six weeks and also Latanoprost which is prostaglandin with concentr
Second group receive Timolol which is a non-specific blocker of beta-adrenergic receptor with concentration of 0.05%, twice daily for six weeks and also Dorzolamide which is Henle's loop diuretic with

Sponsors

Arak University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- Primary open angle gluacoma Exclusion criteria: 1- Secondary open angle glaucoma 2- Narrow-angle glaucoma 3- Allergy to trial drug 4- Ophthalmic herpes zoster 5- Pregnancy and lactation 6- Dry eyes that require use of ophtalmic drops is 5 times or more per day

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Decrease of intraocular pressure. Timepoint: In beginning of the study and the end of six weeks after treatment. Method of measurement: Goldmann Tonometry.

Secondary

MeasureTime frame
Failure of treatment. Timepoint: End of treatment. Method of measurement: Goldmann Tonometry.;Drug side effects. Timepoint: During study. Method of measurement: Clinical evaluation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Reza Rezaei

Arak University of Medical Science

dr.rezarezaei@arakmu.ac.ir+98 86 1313 4715

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026